{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:41:44Z","timestamp":1794573704415,"version":"4.9.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1004","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Drug induced parkinsonism is the second most common cause of parkinsonism in older people after idiopathic Parkinson\u2019s disease (PD). Risk factors for developing drug induced parkinsonism include: older age; female gender; dose and duration of treatment; type of agent used; cognitive impairment; acquired immunodeficiency syndrome (AIDS); tardive dyskinesia; and pre-existing extrapyramidal disorder. In most patients parkinsonism is reversible upon stopping the offending drug, though it may take several months to resolve fully and in some patients it may even persist. In this case, one needs to consider the possibility of PD which has been unmasked by the offending drug, and treatment with dopaminergic agents may be warranted. Drug induced parkinsonism adversely affects the quality of life in older patients and is potentially reversible, highlighting the importance of early recognition of this condition. This article discusses the drugs implicated, as well as the epidemiology, pathophysiology, clinical features, and management of drug induced parkinsonism.<\/jats:p>","DOI":"10.1136\/pgmj.2008.073312","type":"journal-article","created":{"date-parts":[[2009,6,15]],"date-time":"2009-06-15T17:38:07Z","timestamp":1245087487000},"page":"322-326","source":"Crossref","is-referenced-by-count":114,"title":["Drug induced parkinsonism: a common cause of parkinsonism in older people"],"prefix":"10.1093","volume":"85","author":[{"given":"B","family":"Thanvi","sequence":"first","affiliation":[{"name":"South Warwickshire Hospital , Warwick , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Treadwell","sequence":"additional","affiliation":[{"name":"Department of Stroke Medicine, University Hospitals of Leicester NHS Trust , Leicester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,6,15]]},"reference":[{"key":"2023041909291508400_b1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1474-4422(05)70226-X","article-title":"Prevalence of movement disorders in men and women aged 50\u201389 years (Bruneck Study cohort): a population-based study","volume":"4","author":"Wenning","year":"2005","journal-title":"Lancet Neurol"},{"key":"2023041909291508400_b2","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/mds.20806","article-title":"Parkinsonism and Parkinson\u2019s disease in the elderly: a community-based survey in Brazil (the Bambu\u00ed study)","volume":"21","author":"Barbosa","year":"2006","journal-title":"Mov Disord"},{"key":"2023041909291508400_b3","first-page":"112","article-title":"Drug-induced parkinsonism","volume":"55","author":"Kuzuhara","year":"1997","journal-title":"Nippon Rinsho"},{"key":"2023041909291508400_b4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/mds.10362","article-title":"Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain","volume":"18","author":"Benito-Leon","year":"2003","journal-title":"Mov Disord"},{"key":"2023041909291508400_b5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00002512-199405020-00006","article-title":"Drug-induced parkinsonism in the aged. Recognition and prevention","volume":"5","author":"Gershanik","year":"1994","journal-title":"Drugs Aging"},{"key":"2023041909291508400_b6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/mds.21854","article-title":"Failure of recognition of drug-induced parkinsonism in the elderly","volume":"23","author":"Esper","year":"2008","journal-title":"Mov Disord"},{"key":"2023041909291508400_b7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0002-9343(99)80104-1","article-title":"Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study","volume":"99","author":"Avorn","year":"1995","journal-title":"Am J Med"},{"key":"2023041909291508400_b8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/1531-8257(199901)14:1<128::AID-MDS1021>3.0.CO;2-J","article-title":"Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism","volume":"14","author":"Lera","year":"1999","journal-title":"Mov Disord"},{"key":"2023041909291508400_b9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.161.1.160","article-title":"Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients","volume":"161","author":"Janno","year":"2004","journal-title":"Am J Psychiatry"},{"key":"2023041909291508400_b10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00023210-200216010-00003","article-title":"Effects of newer antipsychotics on extrapyramidal function","volume":"16","author":"Tarsy","year":"2002","journal-title":"CNS Drugs"},{"key":"2023041909291508400_b11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/jcp.0b013e318160864f","article-title":"Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia","volume":"28","author":"Cortese","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"2023041909291508400_b12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","article-title":"Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson\u2019s disease psychosis","volume":"29","author":"Merims","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"2023041909291508400_b13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00002826-200401000-00003","article-title":"Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience","volume":"27","author":"Fernandez","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"2023041909291508400_b14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Can J Psychiatry"},{"key":"2023041909291508400_b15","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/mol.107.043786","article-title":"Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs","volume":"73","author":"Fumagalli","year":"2008","journal-title":"Mol Pharmacol"},{"key":"2023041909291508400_b16","first-page":"307","article-title":"Extrapyramidal reactions to metoclopramide and prochlorperazine","volume":"71","author":"Bateman","year":"1989","journal-title":"Q J Med"},{"key":"2023041909291508400_b17","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/archinte.1993.00410120051007","article-title":"The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders","volume":"153","author":"Ganzini","year":"1993","journal-title":"Arch Intern Med"},{"key":"2023041909291508400_b18","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1590\/S0004-282X2004000500008","article-title":"Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine","volume":"62","author":"Fabiani","year":"2004","journal-title":"Arq Neuropsiquiatr"},{"key":"2023041909291508400_b19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/jcbfm.1995.63","article-title":"D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study","volume":"15","author":"Brucke","year":"1995","journal-title":"Journal of Cerebral Flow and Metabolism"},{"key":"2023041909291508400_b20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00002826-199104000-00005","article-title":"Cinnarizine-induced parkinsonism","volume":"14","author":"Gim\u00e9nez-Rold\u00e1n","year":"1991","journal-title":"Clin Neuropharmacol"},{"key":"2023041909291508400_b21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/mds.870100120","article-title":"Parkinsonism induced by amlodipine","volume":"10","author":"Sempere","year":"1995","journal-title":"Mov Disord"},{"key":"2023041909291508400_b22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0006-8993(98)01231-1","article-title":"Nifedipine blocks apamin-induced bursting activity in nigral dopamine-containing neurons","volume":"817","author":"Shepard","year":"1999","journal-title":"Brain Res"},{"key":"2023041909291508400_b23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mds.21188","article-title":"Valproate-induced parkinsonism in epilepsy patients","volume":"22","author":"Jamora","year":"2007","journal-title":"Mov Disord"},{"key":"2023041909291508400_b24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/jnnp.2006.100222","article-title":"Movement disorders in patients taking anticonvulsants","volume":"78","author":"Zadikoff","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023041909291508400_b25","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1054\/jocn.2001.1033","article-title":"A case of parkinsonism due to lithium intoxication: treatment with pramipexole","volume":"9","author":"Dallocchio","year":"2002","journal-title":"J Clin Neurosci"},{"key":"2023041909291508400_b26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0304-3940(90)90416-7","article-title":"Valproic acid selectively reduces the low-threshold (T) calcium current in rat nodose neurons","volume":"116","author":"Kelly","year":"1990","journal-title":"Neurosci Lett"},{"key":"2023041909291508400_b27","first-page":"757","article-title":"Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance","volume":"150","author":"Llau","year":"1994","journal-title":"Rev Neurol (Paris)"},{"key":"2023041909291508400_b28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/00002512-200017050-00004","article-title":"Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations","volume":"17","author":"Caligiuri","year":"2000","journal-title":"Drugs Aging"},{"key":"2023041909291508400_b29","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1212\/01.wnl.0000302255.49113.51","article-title":"Understanding drug-induced parkinsonism: separating pearls from oysters","volume":"70","author":"Alvarez","year":"2008","journal-title":"Neurology"},{"key":"2023041909291508400_b30","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jnnp.51.6.850","article-title":"Neuroleptic-induced Parkinson\u2019s syndrome: clinical features and results of treatment with levodopa","volume":"51","author":"Hardie","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"(Suppl 7)","key":"2023041909291508400_b31","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1002\/mds.10575","article-title":"DAT imaging in drug-induced and psychogenic parkinsonism","volume":"18","author":"Tolosa","year":"2003","journal-title":"Mov Disord"},{"key":"2023041909291508400_b32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/ageing\/afi025","article-title":"Vascular parkinsonism\u2014an important cause of parkinsonism in older people","volume":"34","author":"Thanvi","year":"2005","journal-title":"Age Ageing"},{"key":"2023041909291508400_b33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/030006058000800507","article-title":"A comparison of biperiden hydrochloride (Akineton) and benzhexol (Artane) in the treatment of drug-induced parkinsonism","volume":"8","author":"Magnus","year":"1980","journal-title":"J Int Med Res"},{"key":"2023041909291508400_b34","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1176\/ajp.133.8.940","article-title":"Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism","volume":"133","author":"Fann","year":"1976","journal-title":"Am J Psychiatry"},{"key":"2023041909291508400_b35","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/pgmj.2004.032029","article-title":"Psychosis in Parkinson\u2019s disease","volume":"81","author":"Thanvi","year":"2005","journal-title":"Postgrad Med J"},{"key":"2023041909291508400_b36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2515\/therapie:2004021","article-title":"Drug-induced Parkinson syndromes","volume":"59","author":"Nguyen","year":"2004","journal-title":"Therapie"},{"key":"2023041909291508400_b37","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/jnnp.2005.073999","article-title":"Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism","volume":"77","author":"Lee","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023041909291508400_b38","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1136\/jnnp.2007.121285","article-title":"Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism","volume":"78","author":"Lee","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023041909291508400_b39","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1007\/s00415-008-0993-5","article-title":"Neuroleptic-induced parkinsonism is associated with olfactory dysfunction","volume":"255","author":"Kr\u00fcger","year":"2008","journal-title":"J Neurol"},{"key":"2023041909291508400_b40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.parkreldis.2007.07.009","article-title":"Subjective cognitive dysfunction associated with drug-induced parkinsonism in schizophrenia","volume":"14","author":"Kim","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"2023041909291508400_b41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hup.1009","article-title":"Non-motor cognitive-perceptual dysfunction associated with drug-induced parkinsonism","volume":"24","author":"Kim","year":"2009","journal-title":"Hum Psychopharmacol"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/85\/1004\/322\/50020515\/postgradmedj-85-322.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/85\/1004\/322\/50020515\/postgradmedj-85-322.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T09:40:46Z","timestamp":1681897246000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/85\/1004\/322\/7007446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,1]]},"references-count":41,"journal-issue":{"issue":"1004","published-online":{"date-parts":[[2009,6,15]]},"published-print":{"date-parts":[[2009,6,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.2008.073312","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,6]]},"published":{"date-parts":[[2009,6,1]]}}}